Every year, the BIO International Convention brings together more than 20,000 leaders from across the global life sciences ...

KIT-targeting antibody biotech Jasper Therapeutics is being renewed via a merger with Nasdaq-listed Kira Pharmaceuticals—but ...

Another biotech is squeezing into the crowded IPO waiting room just in time for the weekend. | Another biotech is squeezing ...

GSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as the key 2026 catalyst for the ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Dimerix has bought an acute kidney injury (AKI) drug from Mission Therapeutics, paying (PDF) $5 million upfront and ...

Jennifer Doudna, Ph.D., the Nobel Laureate best known for co-inventing the CRISPR system that has become the foundation for ...

Takeda has unveiled more data from its phase 3 trials of zasocitinib, demonstrating that the once-daily pill was able to ...

Eli Lilly has struck a deal to buy AtaiBeckley for $2.8 billion upfront, continuing its takeover spree to move into a ...

When Axiom Biosciences' stem cell therapy demonstrated a 0% mortality rate over two years in potentially fatal newborn ...

Vogenx has joined the growing queue for the Nasdaq, as the metabolic biotech eyes an IPO to fund its SGLT1 inhibitor. | ...

A phase 2 trial of InnoCare Pharma’s TYK2 inhibitor soficitinib in nonsegmental vitiligo has hit its primary endpoint, clearing the Chinese biotech to advance into the phase 3 p ...